Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-up

Página do item simplificado
dc.contributor.authorWu, Lihteh
dc.contributor.authorArevalo, Jose Fernando
dc.contributor.authorRoca, Jose Antonio
dc.contributor.authorMaia, Mauricio [UNIFESP]
dc.contributor.authorBerrocal, Maria Hortensia
dc.contributor.authorRodriguez, Francisco J.
dc.contributor.authorEvans, Teodoro
dc.contributor.authorCosta, Rogerio Alves [UNIFESP]
dc.contributor.authorCardillo, José Augusto [UNIFESP]
dc.contributor.authorPACORES
dc.contributor.institutionInst Cirugia Ocular
dc.contributor.institutionClin Oftalmol Ctr
dc.contributor.institutionClin Ricardo Palma
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniv Puerto Rico
dc.contributor.institutionUniv Rosario
dc.contributor.institutionHosp Olhos Araraquara
dc.date.accessioned2018-06-18T11:35:36Z
dc.date.available2018-06-18T11:35:36Z
dc.date.issued2008-02-01
dc.description.abstractPurpose: To report the 6-month anatomical and visual outcomes after injecting two different doses of intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion (BRVO).Methods: An interventional, retrospective multicenter study of 45 eyes that were treated with at least one intravitreal injection (24 eyes, 1.25 mg; 21 eyes, 2.5 mg) of bevacizumab is reported. The main outcome measures were the central 1-mm macular thickness (CMT) and the change in ETDRS lines of best-corrected visual acuity (BCVA) at 6 months.Results: Forty-five eyes were injected on average 26.1 months (range, 3-86 months) after the diagnosis. The average follow-up was 35.2 weeks (range, 24-52 weeks). All patients completed at least 6 months of follow-up. In the 1.25-mg dose group, at 1 month, there was an average gain of 4.5 lines of BCVA; at 3 months, 5.1 lines of BCVA; and at 6 months, 5.1 lines of BCVA (P < 0.005). In the 2.5-mg dose group, at 1 month, there was an average gain of 2.3 lines of BCVA; at 3 months, 3.8 lines of BCVA; and at 6 months, 4.8 lines of BCVA (P = 0.05). In the 1.25-mg dose group, the mean CMT +/- SD decreased from 461 +/- 211 mu m at baseline to 321 +/- 152 mu m at 1 month, 273 +/- 99 mu m at 3 months, and 277 +/- 114 mu m at 6 months (P = 0.0002). In the 2.5-mg group, the mean CMT +/- SD decreased from 385 +/- 168 mu m at baseline to 279 +/- 111 mu m at 1 month, 249 +/- 97 mu m at 3 months, and 240 +/- 93 mu m at 6 months (P = 0.011).Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections and anatomical and functional outcomes. Intravitreal injection of bevacizumab at doses up to 2.5 mg appears to be effective in improving BCVA and reducing CMT in BRVO in the short term. Multiple injections are needed in a large number of eyes for continued control of macular edema and preservation of visual acuity in the short term. Longer studies are needed to determine what role if any intravitreal injection of bevacizumab may play in the long-term treatment of this condition.en
dc.description.affiliationInst Cirugia Ocular, San Jose, Costa Rica
dc.description.affiliationClin Oftalmol Ctr, Retina & Vitreous Serv, Caracas, Venezuela
dc.description.affiliationClin Ricardo Palma, Lima, Peru
dc.description.affiliationUniv Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil
dc.description.affiliationUniv Puerto Rico, San Juan, PR 00936 USA
dc.description.affiliationUniv Rosario, Fdn Oftalmol Nacl, Bogota, Colombia
dc.description.affiliationHosp Olhos Araraquara, Retinal Diagnost & Treatment Div, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Inst Visao, Dept Oftalmol, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent212-219
dc.identifierhttp://dx.doi.org/10.1097/IAE.0b013e3181619bee
dc.identifier.citationRetina-the Journal Of Retinal And Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 28, n. 2, p. 212-219, 2008.
dc.identifier.doi10.1097/IAE.0b013e3181619bee
dc.identifier.issn0275-004X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/45215
dc.identifier.wosWOS:000253460800003
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofRetina-the Journal Of Retinal And Vitreous Diseases
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectbevacizumaben
dc.subjectbranch retinal vein occlusionen
dc.subjectmacular edemaen
dc.subjectvascular endothelial growth factoren
dc.titleComparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-upen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos